<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804644</url>
  </required_header>
  <id_info>
    <org_study_id>NRG-CC009</org_study_id>
    <secondary_id>NCI-2020-11651</secondary_id>
    <secondary_id>NRG-CC009</secondary_id>
    <secondary_id>NRG-CC009</secondary_id>
    <secondary_id>NRG-CC009</secondary_id>
    <secondary_id>UG1CA189867</secondary_id>
    <nct_id>NCT04804644</nct_id>
  </id_info>
  <brief_title>Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability</brief_title>
  <official_title>Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NRG Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial compares the effect of stereotactic radiosurgery to standard of care&#xD;
      memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of&#xD;
      the brain) for the treatment of small cell lung cancer that has spread to the brain.&#xD;
      Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high&#xD;
      dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole&#xD;
      brain radiation therapy delivers a low dose of radiation to the entire brain including the&#xD;
      normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT)&#xD;
      decreases the amount of radiation that is delivered to the hippocampus which is a brain&#xD;
      structure that is important for memory. The drug, memantine, is also often given with whole&#xD;
      brain radiotherapy because it may decrease the risk of side effects related to thinking and&#xD;
      memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking&#xD;
      compared to standard of care HA-WBRT plus memantine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine whether stereotactic radiosurgery (SRS) relative to whole brain radiotherapy&#xD;
      with hippocampal avoidance (HA-WBRT) plus memantine hydrochloride (memantine) for brain&#xD;
      metastases from small cell lung cancer (SCLC) prevents cognitive function failure as measured&#xD;
      by cognitive decline on a battery of tests: the Hopkins Verbal Learning Test - Revised&#xD;
      (HVLT-R), Controlled Oral Word Association (COWA) test, and the Trail Making Test (TMT).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine whether SRS relative to HA-WBRT plus memantine for brain metastases from SCLC&#xD;
      preserves cognitive function as separately measured by the HVLT-R, COWA, TMT Parts A and B,&#xD;
      and Clinical Trial Battery Composite (CTB COMP).&#xD;
&#xD;
      II. Assess perceived difficulties in cognitive abilities using Patient Reported Outcomes&#xD;
      Measurement Information System (PROMIS) after SRS relative to HA-WBRT plus memantine for&#xD;
      brain metastases from SCLC.&#xD;
&#xD;
      III. Assess symptom burden using the MD Anderson Symptom Inventory for brain tumor (MDASI-BT)&#xD;
      after SRS relative to HA-WBRT plus memantine for brain metastases from SCLC.&#xD;
&#xD;
      IV. Compare cumulative incidence of intracranial disease progression after SRS relative to&#xD;
      HA-WBRT plus memantine for brain metastases from SCLC.&#xD;
&#xD;
      V. Compare overall survival after SRS relative to HA-WBRT plus memantine for brain metastases&#xD;
      from SCLC.&#xD;
&#xD;
      VI. Compare cumulative incidence of neurologic death after SRS relative to HA-WBRT plus&#xD;
      memantine for brain metastases from SCLC.&#xD;
&#xD;
      VII. Compare the number of salvage procedures used to manage recurrent intracranial disease&#xD;
      following SRS relative to HA-WBRT plus memantine for SCLC brain metastases.&#xD;
&#xD;
      VIII. Compare adverse events between the treatment arms according to the National Cancer&#xD;
      Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0&#xD;
      criteria.&#xD;
&#xD;
      IX. Compare the risk of developing cerebral necrosis between SRS and HA-WBRT plus memantine&#xD;
      in patients receiving concurrent immunotherapy.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Compare cumulative incidence of local brain recurrence, distant brain relapse, and&#xD;
      leptomeningeal dissemination after SRS relative to HA-WBRT plus memantine for brain&#xD;
      metastases from SCLC.&#xD;
&#xD;
      II. Compare the cost of brain-related therapies and quality-adjusted life years in patients&#xD;
      who receive SRS relative to HA-WBRT plus memantine for brain metastases from SCLC.&#xD;
&#xD;
      III. Evaluate the time delay to salvage WBRT or HA-WBRT in patients enrolled on the SRS arm.&#xD;
&#xD;
      IV. Evaluate whether a time delay for chemotherapy in patients receiving HA-WBRT plus&#xD;
      memantine relative to SRS for brain metastases from SCLC has an effect on overall survival.&#xD;
&#xD;
      V. Evaluate baseline magnetic resonance (MR) imaging biomarkers of white matter injury and&#xD;
      hippocampal volumetry as potential predictors of cognitive decline and differential benefit&#xD;
      from SRS relative to HA-WBRT plus memantine for brain metastases from SCLC.&#xD;
&#xD;
      VI. Evaluate the correlation between neurocognitive functioning and patient-reported&#xD;
      outcomes.&#xD;
&#xD;
      VII. Collect serum, plasma and imaging studies for future translational research analyses.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients undergo SRS over 1 day (in some cases several days).&#xD;
&#xD;
      ARM II: Patients undergo HA-WBRT once daily (QD) for 2 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients also receive memantine orally (PO) QD or twice&#xD;
      daily (BID) for up to 24 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 2-3 months for 1 year,&#xD;
      and then every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Neurocognitive Failure</measure>
    <time_frame>1 year</time_frame>
    <description>Neurocognitive failure is the first failure, defined as neurocognitive decline (decline vs. no decline) using the reliable change index (RCI) on at least one of the following tests: Hopkins Verbal Learning Test - Revised (HVLT-R), Controlled Oral Word Association (COWA) test, or Trail Making Test (TMT) Parts A and B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preservation of Neurocognitive Function</measure>
    <time_frame>1 year</time_frame>
    <description>A mixed effects model will be used to assess changes of standardized neurocognitive scores across time using all available data while adjusting for stratification variables and other baseline characteristics. For discrete time point analyses, the change from baseline to each follow-up time point, will be calculated and compared between treatment arms using a t-test or Wilcoxon-Mann-Whitney test, depending on the normality of the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Difficulties in Cognition</measure>
    <time_frame>1 year</time_frame>
    <description>Measured by Patient Reported Outcomes Measurement Information System (PROMIS). For discrete time point analyses, the change from baseline to each follow-up time point, will be calculated and compared between treatment arms using a t-test or Wilcoxon-Mann-Whitney test, depending on the normality of the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Burden</measure>
    <time_frame>1 year</time_frame>
    <description>Measured by MD Anderson Symptom Inventory for brain tumor (MDASI-BT). Four subscales (symptom severity, symptom interference, neurologic factor, and cognitive factor score) as well as certain individual items (fatigue, neurologic factor items, and cognitive factor items) of the MDASI-BT will be analyzed. Mixed effects models will be used to assess changes of the four subscale scores (symptom severity, symptom interference, neurologic factor, and cognitive factor score) across time using all available data while adjusting for stratification variables and other baseline characteristics. For discrete time point analyses, the change from baseline to each follow-up time point, will be calculated and compared between treatment arms using a t-test or Wilcoxon-Mann-Whitney test, depending on the normality of the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of randomization to the date of death, or otherwise, the last follow-up date on which the patient was reported alive, assessed up to 10 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method (Kaplan 1958), and differences between treatment arms will be tested using the log rank test (Mantel 1966). The Cox proportional hazard model (Cox 1972) will be performed with the stratification variables and other baseline characteristics as fixed variables to assess the treatment effect while adjusting for patient specific risk factors such as number of brain metastases and its interaction with treatment, KPS, and time to salvage chemotherapy as a time varying covariate. A two-sided significance level of 0.05 will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Neurologic Death</measure>
    <time_frame>From the date of randomization to the date of neurologic death, assessed up to 10 years</time_frame>
    <description>Gray's test will be used to assess between treatment arm comparisons (Gray 1988). Cause-specific Cox proportional hazards models will be used to evaluate the effect of stratification variables (DS-GPA and prior NCF testing exposure) and other baseline characteristics, such as KPS, and number of brain metastases and its interaction with treatment arm. A two-sided significance level of 0.05 will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salvage procedures used to manage recurrent intracranial disease</measure>
    <time_frame>10 years</time_frame>
    <description>Will be collected and descriptively compared between arms using Chi-square tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>10 years</time_frame>
    <description>Graded by Common Terminology Criteria for Adverse Events version 5.0. Counts of all adverse events (AEs) by grade will be provided by treatment arm. Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm. The rate of grade 3+ AEs related to treatment and the rate of grade 3+ AEs regardless of relationship to treatment will be compared between treatment arms using a Chi-square test at a two-sided significance level of 0.05.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to local brain recurrence (in brain lesions present at trial enrollment and treated with either stereotactic radiosurgery [SRS] or hippocampal-avoidant whole brain radiotherapy [HA-WBRT])</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to incidence of distant brain relapses</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to leptomeningeal dissemination</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time delay to salvage WBRT or HA-WBRT in patients on the SRS arm</measure>
    <time_frame>Baseline to first salvage treatment, assessed up to 10 years</time_frame>
    <description>Gray's test will be used to compare treatment arms (Gray 1988).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Lung Small Cell Carcinoma</condition>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <condition>Recurrent Lung Small Cell Carcinoma</condition>
  <condition>Stage IV Lung Cancer AJCC v8</condition>
  <condition>Stage IVA Lung Cancer AJCC v8</condition>
  <condition>Stage IVB Lung Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm I (SRS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SRS over 1 day (in some cases several days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (HA-WBRT, memantine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients also undergo HA-WBRT QD for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients will also receive memantine PO QD or BID for up to 24 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (HA-WBRT, memantine)</arm_group_label>
    <other_name>Ebixia</other_name>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurocognitive Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (SRS)</arm_group_label>
    <arm_group_label>Arm II (HA-WBRT, memantine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Undergo SRS</description>
    <arm_group_label>Arm I (SRS)</arm_group_label>
    <other_name>Stereotactic External Beam Irradiation</other_name>
    <other_name>stereotactic external-beam radiation therapy</other_name>
    <other_name>Stereotactic Radiation Therapy</other_name>
    <other_name>Stereotactic Radiotherapy</other_name>
    <other_name>stereotaxic radiation therapy</other_name>
    <other_name>stereotaxic radiosurgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole-Brain Radiotherapy</intervention_name>
    <description>Undergo HA-WBRT</description>
    <arm_group_label>Arm II (HA-WBRT, memantine)</arm_group_label>
    <other_name>WBRT</other_name>
    <other_name>whole-brain radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically (histologically or cytologically) proven diagnosis of small cell lung&#xD;
             cancer within 5 years of registration. If the original histologic proof of malignancy&#xD;
             is greater than 5 years, then pathological (i.e., more recent) confirmation is&#xD;
             required (e.g., from a systemic or brain metastasis);&#xD;
&#xD;
               -  Patients with de novo or recurrent small cell lung cancer are permitted.&#xD;
&#xD;
          -  Ten or fewer brain metastases =&lt; 3 cm in largest diameter and outside a 5-mm margin&#xD;
             around either hippocampus must be visible on contrast-enhanced magnetic resonance&#xD;
             imaging (MRI) performed =&lt; 21 days prior to study entry.&#xD;
&#xD;
               -  Brain metastases can be diagnosed synchronous to the initial diagnosis of small&#xD;
                  cell lung cancer or metachronous to the initial diagnosis and management of small&#xD;
                  cell lung cancer.&#xD;
&#xD;
               -  The total tumor volume must be 30 cm^3 or less. Lesion volume will be&#xD;
                  approximated by measuring the lesion's three perpendicular diameters on contrast&#xD;
                  enhanced, T1-weighted MRI and the product of those diameters will be divided by 2&#xD;
                  to estimate the lesion volume (e.g. xyz/2). Alternatively, direct volumetric&#xD;
                  measurements via slice by slice contouring on a treatment planning software&#xD;
                  package can be used to calculate the total tumor volume.&#xD;
&#xD;
               -  Brain metastases must be diagnosed on MRI, which will include the following&#xD;
                  elements:&#xD;
&#xD;
                    -  REQUIRED MRI ELEMENTS&#xD;
&#xD;
                         -  Post gadolinium contrast-enhanced T1-weighted three-dimensional (3D)&#xD;
                            spoiled gradient (SPGR). Acceptable 3D SPGR sequences include&#xD;
                            magnetization prepared 3D gradient recalled echo (GRE) rapid gradient&#xD;
                            echo (MP-RAGE), turbo field echo (TFE) MRI, BRAVO (Brain Volume&#xD;
                            Imaging) or 3D Fast FE (field echo). The T1-weighted 3D scan should use&#xD;
                            the smallest possible axial slice thickness, not to exceed 1.5 mm.&#xD;
&#xD;
                         -  Pre-contrast T1 weighted imaging (3D imaging sequence strongly&#xD;
                            encouraged).&#xD;
&#xD;
                         -  A minimum of one axial T2 FLAIR (preferred) or T2 sequence is required.&#xD;
                            This can be acquired as a two dimensional (2D) or 3D image. If 2D, the&#xD;
                            images should be obtained in the axial plane.&#xD;
&#xD;
                    -  ADDITIONAL RECOMMENDATIONS&#xD;
&#xD;
                         -  Recommendation is that an axial T2 FLAIR (preferred) sequence be&#xD;
                            performed instead of a T2 sequence.&#xD;
&#xD;
                         -  Recommendation is that that pre-contrast 3D T1 be performed with the&#xD;
                            same parameters as the post-contrast 3D T1.&#xD;
&#xD;
                         -  Recommendation is that imaging be performed on a 3 Tesla (3T) MRI.&#xD;
&#xD;
                         -  Recommendation is that the study participants be scanned on the same&#xD;
                            MRI instrument at each time point.&#xD;
&#xD;
                         -  Recommendation is that if additional sequences are obtained, these&#xD;
                            should meet the criteria outlined in Kaufmann et al., 2020.&#xD;
&#xD;
                         -  If additional sequences are obtained, total imaging time should not&#xD;
                            exceed 60 minutes.&#xD;
&#xD;
          -  History/physical examination within 28 days prior to registration&#xD;
&#xD;
          -  Age &gt;= 18&#xD;
&#xD;
          -  Karnofsky performance status of &gt;= 70 within 28 days prior to registration&#xD;
&#xD;
          -  Creatinine clearance &gt;= 30 ml/min (within 28 days prior to registration)&#xD;
&#xD;
          -  Following the diagnosis of brain metastases, patients can initiate and treat with&#xD;
             systemic (chemotherapy and/or immunotherapy) before enrollment only if their brain&#xD;
             metastases are asymptomatic and not located in eloquent locations (e.g., brainstem,&#xD;
             pre-/post-central gyrus, visual cortex). However, within 21 days prior to enrollment,&#xD;
             brain MRI must be repeated to confirm eligibility.&#xD;
&#xD;
               -  Patients with symptomatic brain metastases and/or brain metastases in eloquent&#xD;
                  locations (e.g., brainstem, pre-/post central gyrus, visual cortex) are eligible&#xD;
                  for enrollment on the trial; however, the specific treatment approach of starting&#xD;
                  with systemic therapy alone and delaying brain radiation is not recommended for&#xD;
                  these patients.&#xD;
&#xD;
          -  Concurrent immunotherapy with brain radiation (SRS or HA-WBRT) is permitted.&#xD;
&#xD;
          -  Negative urine or serum pregnancy test (in women of childbearing potential) within 14&#xD;
             days prior to registration. Women of childbearing potential and men who are sexually&#xD;
             active must use contraception while on study.&#xD;
&#xD;
          -  Patients may have had prior intracranial surgical resection. Patients must have&#xD;
             completed prior intracranial surgical resection at least 14 days prior to&#xD;
             registration.&#xD;
&#xD;
          -  Because neurocognitive testing is the primary goal of this study, patients must be&#xD;
             proficient in English or French Canadian.&#xD;
&#xD;
          -  The patient must provide study-specific informed consent prior to study entry.&#xD;
&#xD;
               -  Patients with impaired decision-making capacity are not permitted on study.&#xD;
&#xD;
          -  ELIGIBILITY CRITERIA PRIOR TO STEP 2 REGISTRATION&#xD;
&#xD;
          -  The following baseline neurocognitive tests must be completed within 21 days prior to&#xD;
             Step 2 registration: HVLT-R, TMT, and COWA. The neurocognitive test will be uploaded&#xD;
             into RAVE for evaluation by Dr. Wefel. Once the upload is complete, within 1 business&#xD;
             day a notification will be sent via email to the RA to proceed to Step 2.&#xD;
&#xD;
               -  NOTE: Completed baseline neurocognitive tests can be uploaded at the time of Step&#xD;
                  1 registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned infusion of cytotoxic chemotherapy on the same day as SRS or HA-WBRT&#xD;
             treatment. Patients may have had prior chemotherapy. Concurrent immunotherapy is&#xD;
             permitted.&#xD;
&#xD;
          -  Prior allergic reaction to memantine.&#xD;
&#xD;
          -  Intractable seizures while on adequate anticonvulsant therapy; more than 1 seizure per&#xD;
             month for the past 2 months.&#xD;
&#xD;
          -  Patients with definitive leptomeningeal metastases.&#xD;
&#xD;
          -  Known history of demyelinating disease such as multiple sclerosis.&#xD;
&#xD;
          -  Contraindication to MR imaging such as implanted metal devices that are&#xD;
             MRI-incompatible, allergy to MRI contrast that cannot be adequately addressed with&#xD;
             pre-contrast medications, or foreign bodies that preclude MRI imaging. (Questions&#xD;
             regarding MRI compatibility of implanted objects should be reviewed with the Radiology&#xD;
             Department performing the MRI).&#xD;
&#xD;
          -  Current use of (other N-methyl-D-aspartate [NMDA] antagonists) amantadine, ketamine,&#xD;
             or dextromethorphan.&#xD;
&#xD;
          -  Radiographic evidence of hydrocephalus or other architectural change of the&#xD;
             ventricular system resulting in significant anatomic distortion of the hippocampus,&#xD;
             including placement of external ventricular drain or ventriculoperitoneal shunt.&#xD;
&#xD;
               -  Mild cases of hydrocephalus not resulting in significant anatomic distortion of&#xD;
                  the hippocampus are permitted.&#xD;
&#xD;
          -  Prior radiotherapy to the brain, including SRS, WBRT, or prophylactic cranial&#xD;
             irradiation (PCI).&#xD;
&#xD;
          -  Severe, active co-morbidity defined as follows:&#xD;
&#xD;
               -  Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the last 6 months&#xD;
&#xD;
               -  Transmural myocardial infarction within the last 6 months&#xD;
&#xD;
               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time&#xD;
                  of registration&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease exacerbation or other acute respiratory&#xD;
                  illness precluding study therapy at the time of registration&#xD;
&#xD;
               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinai Gondi</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>323-865-0451</phone>
    </contact>
    <investigator>
      <last_name>Jason C. Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>323-865-0451</phone>
    </contact>
    <investigator>
      <last_name>Jason C. Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>404-303-3355</phone>
      <email>ClinicalTrials@northside.com</email>
    </contact>
    <investigator>
      <last_name>Rodolfo E. Bordoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital-Cherokee</name>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <zip>30115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>404-303-3355</phone>
      <email>clinical.trials@northside.com</email>
    </contact>
    <investigator>
      <last_name>Rodolfo E. Bordoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital-Forsyth</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>404-303-3355</phone>
      <email>clinicaltrials@northside.com</email>
    </contact>
    <investigator>
      <last_name>Rodolfo E. Bordoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centralia Oncology Clinic</name>
      <address>
        <city>Centralia</city>
        <state>Illinois</state>
        <zip>62801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>217-876-4762</phone>
      <email>morganthaler.jodi@mhsil.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle on Vermilion</name>
      <address>
        <city>Danville</city>
        <state>Illinois</state>
        <zip>61832</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Kalika P. Sarma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists of Illinois - Decatur</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>217-876-4762</phone>
      <email>morganthaler.jodi@mhsil.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>217-876-4762</phone>
      <email>morganthaler.jodi@mhsil.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Kishwaukee</name>
      <address>
        <city>DeKalb</city>
        <state>Illinois</state>
        <zip>60115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>630-352-5360</phone>
      <email>Donald.Smith3@nm.org</email>
    </contact>
    <investigator>
      <last_name>Vinai Gondi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Physician Group-Effingham</name>
      <address>
        <city>Effingham</city>
        <state>Illinois</state>
        <zip>62401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Kalika P. Sarma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crossroads Cancer Center</name>
      <address>
        <city>Effingham</city>
        <state>Illinois</state>
        <zip>62401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>217-876-4762</phone>
      <email>morganthaler.jodi@mhsil.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Delnor</name>
      <address>
        <city>Geneva</city>
        <state>Illinois</state>
        <zip>60134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>630-352-5360</phone>
      <email>Donald.Smith3@nm.org</email>
    </contact>
    <investigator>
      <last_name>Vinai Gondi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Physician Group-Mattoon/Charleston</name>
      <address>
        <city>Mattoon</city>
        <state>Illinois</state>
        <zip>61938</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Kalika P. Sarma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of O'Fallon</name>
      <address>
        <city>O'Fallon</city>
        <state>Illinois</state>
        <zip>62269</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>217-876-4762</phone>
      <email>morganthaler.jodi@mhsil.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Kalika P. Sarma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Kalika P. Sarma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Warrenville</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>630-352-5360</phone>
      <email>Donald.Smith3@nm.org</email>
    </contact>
    <investigator>
      <last_name>Vinai Gondi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Bird Perkins Cancer Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>225-215-1353</phone>
      <email>clinicalresearch@marybird.com</email>
    </contact>
    <investigator>
      <last_name>David S. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>443-481-1320</phone>
      <email>research@aahs.org</email>
    </contact>
    <investigator>
      <last_name>Angel E. Torano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Franklin Square Medical Center/Weinberg Cancer Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>443-777-7364</phone>
    </contact>
    <investigator>
      <last_name>Kamila Nowak Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Canton</name>
      <address>
        <city>Canton</city>
        <state>Michigan</state>
        <zip>48188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Canton</name>
      <address>
        <city>Canton</city>
        <state>Michigan</state>
        <zip>48188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Chelsea</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Chelsea</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHA Hematology Oncology Consultants-Ann Arbor</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Samir Narayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Joe Lueken Cancer Center</name>
      <address>
        <city>Bemidji</city>
        <state>Minnesota</state>
        <zip>56601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>218-333-5000</phone>
      <email>OncologyClinicalTrialsFargo@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Cape Girardeau</city>
        <state>Missouri</state>
        <zip>63703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>573-334-2230</phone>
      <email>sfmc@sfmc.net</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkland Health Center - Farmington</name>
      <address>
        <city>Farmington</city>
        <state>Missouri</state>
        <zip>63640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>314-996-5569</phone>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>314-996-5569</phone>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sainte Genevieve County Memorial Hospital</name>
      <address>
        <city>Sainte Genevieve</city>
        <state>Missouri</state>
        <zip>63670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>314-996-5569</phone>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>417-269-4520</phone>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Sullivan Hospital</name>
      <address>
        <city>Sullivan</city>
        <state>Missouri</state>
        <zip>63080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>314-996-5569</phone>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Outpatient Center-Sunset Hills</name>
      <address>
        <city>Sunset Hills</city>
        <state>Missouri</state>
        <zip>63127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>314-996-5569</phone>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benefis Healthcare- Sletten Cancer Institute</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>406-969-6060</phone>
      <email>mccinfo@mtcancer.org</email>
    </contact>
    <investigator>
      <last_name>John M. Schallenkamp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>315-464-5476</phone>
    </contact>
    <investigator>
      <last_name>Michael D. Mix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>336-713-6771</phone>
    </contact>
    <investigator>
      <last_name>Christina K. Cramer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Bismarck Medical Center</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>701-323-5760</phone>
      <email>OncologyClinicalTrialsFargo@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Broadway Medical Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>701-323-5760</phone>
      <email>OncologyClinicalTrialsFargo@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Roger Maris Cancer Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>701-234-6161</phone>
      <email>OncologyClinicalTrialsFargo@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Tyler Gunter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center-Gaffney</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Jeremy M. Kilburn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center-Pelham</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Jeremy M. Kilburn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Jeremy M. Kilburn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MGC Hematology Oncology-Union</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Jeremy M. Kilburn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>605-322-3095</phone>
      <email>OncRegulatory@avera.org</email>
    </contact>
    <investigator>
      <last_name>Joel Grow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

